|Bid||3.18 x 1100|
|Ask||6.99 x 1400|
|Day's Range||4.45 - 4.66|
|52 Week Range||3.34 - 12.45|
|Beta (3Y Monthly)||3.16|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.00|
Merrimack (MACK) discourages with Q3 loss, falling shy of estimates as well as deteriorates from the year-ago quarter's figure. Also, the company fails to reap any revenues in the period.
NEW YORK, Nov. 09, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
The biotech said it has also "retained external advisors to explore strategic alternatives," suggesting it may consider a sale.
- Company to initiate corporate restructuring, including ~60% reduction in force and significant reduction in operating expenses; potential to extend runway into at least 2H 2022 to preserve ability to ...
On Wednesday, Nov. 7, Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release. Earnings ...
The call will provide an update on Merrimack's pipeline, including the results of its portfolio review, as well as a summary of its third quarter 2018 financial results. A listen-only webcast of the call will be available in the Investors section of Merrimack's website, investors.merrimack.com, and a replay of the call will be archived there for six weeks. Merrimack is a biopharmaceutical company based in Cambridge, Massachusetts that is outthinking cancer to ensure that patients and their families live fulfilling lives.
Merrimack, which focuses on therapies for biomarker-defined cancer, said it has terminated a study dubbed SHERLOC, which evaluated its MM-121 in combination with docetaxel in patients with heregulin-positive non-small cell lung cancer, or NSCLC. Docetaxel is a chemotherapy medication used to treat several cancers, including breast cancer, head and neck cancer, prostate cancer and NSCLC.
Shares of Merrimack Pharmaceuticals Inc. plummeted 35% toward a record low in premarket trade Friday, after the biopharmaceutical company said it terminated a phase 2 trial of its non-small cell lung cancer treatment after it failed to improve progression free survival. "Since futility was observed, the decision was made to terminate the study," the company said in a statement. Merrimack said it is implementing a review of its drug candidate pipeline, and will provide an update on its Nov. 7 conference call following third-quarter results. The stock had tumbled 50% year to date through Thursday, while the iShares Nasdaq Biotechnology ETF had gained 5.8% and the S&P 500 had tacked on 3.6%.
CAMBRIDGE, Mass., Oct. 19, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced the termination of the SHERLOC study, its randomized, open-label Phase 2 clinical trial evaluating MM-121 in combination with docetaxel in patients with heregulin positive NSCLC. Based on these results, Merrimack is implementing a comprehensive review of its drug candidate pipeline, including assessing the impact of these results on the continued development of MM-121. MM-121 is also currently being evaluated in the SHERBOC study, a Phase 2 clinical trial evaluating MM-121 in combination with fulvestrant, versus fulvestrant alone, in patients with heregulin positive, hormone receptor positive, ErbB2 (HER2) negative, metastatic breast cancer.
NEW YORK, Oct. 16, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Merrimack (MACK) focuses on the development of its two early-stage pipeline candidates, MM-121 and MM-310. The candidates have been progressing well and are imperative to the company's growth.
CAMBRIDGE, Mass., Sept. 20, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced that it has received a $5 million milestone payment from Shire, triggered by the sale of ONIVYDE in the first major non-European, non-Asian country, pursuant to the terms of Merrimack's asset sale to Ipsen in 2017. "Since the start of the third quarter, Merrimack has received $38 million in non-dilutive capital, including two milestone payments from Shire totaling $23 million," said Richard Peters, M.D., Ph.D., President and Chief Executive Officer of Merrimack. The terms of the Company's asset sale to Ipsen in 2017 entitled Merrimack to receive up to an aggregate of $33.0 million in net milestone payments from Shire, of which Merrimack has now received $23.0 million, including this milestone and the $18.0 million payment in August 2018 resulting from the sale of ONIVYDE in two additional major European countries.
Merrimack (MACK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CAMBRIDGE, Mass., Sept. 6, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced that it has completed enrollment in its ongoing SHERLOC study, a Phase 2 clinical trial evaluating its lead investigational drug candidate, MM-121, in patients with heregulin positive NSCLC. "We believe the robust clinical interest we have seen in the SHERLOC study reflects the significant unmet medical need among this patient population," said J. Marc Pipas, M.D., Merrimack's Senior Medical Director and Project Leader for MM-121. The SHERLOC study is a global, randomized, biomarker-selected, open-label Phase 2 clinical trial of MM-121 in combination with docetaxel, versus docetaxel alone, in patients with heregulin positive NSCLC.
Zacks.com highlights: American Woodmark, Adverum Biotechnologies, Merrimack Pharmaceuticals, Athene Holding and M&T Bank
Merrimack's (MACK) loss is wider than expected in Q2 but narrower than the year-ago quarter's deficit. Meanwhile, the company did not generate any revenues in the reported quarter.
- $18 million milestone payment received from Shire; Company continues to strengthen cash position from non-dilutive sources - - Two clinical readouts anticipated in 2018: randomized Phase 2 SHERLOC study ...
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 8:30:00 ...
On Merrimack's (MACK) second-quarter 2018 conference call, investor focus will be on the company's progress with pipeline candidates.